|
1
|
Wilhelm SM, Dumas J, Adnane L, Lynch M,
Carter CA, Schütz G, Thierauch KH and Zopf D: Regorafenib (BAY
73-4506): A new oral multikinase inhibitor of angiogenic, stromal
and oncogenic receptor tyrosine kinases with potent preclinical
antitumor activity. Int J Cancer. 129:245–255. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu
J, Bai Y, Chi Y, Wang L, et al: Regorafenib plus best supportive
care versus placebo plus best supportive care in Asian patients
with previously treated metastatic colorectal cancer (CONCUR): A
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol. 16:619–629. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yoshino K, Manaka D, Kudo R, Kanai S,
Mitsuoka E, Kanto S, Hamasu S, Konishi S and Nishitai R: Metastatic
colorectal cancer responsive to regorafenib for 2 years: A case
report. J Med Case Rep. 11(227)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
U.S. Department of Health and Human
Services: Common Terminology Criteria for Adverse Events (CTCAE).
Version 5.0. U.S. Department of Health and Human Services,
Washington, DC, 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
|
|
6
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kawasaki K, Hamamoto Y, Adachi M, Kanai T
and Takaishi H: Early tumor cavitation with regorafenib in
metastatic colorectal cancer: A case report. Oncol Lett.
11:231–233. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Moriwaki T, Fukuoka S, Taniguchi H,
Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama
C, Denda T, et al: Propensity score analysis of regorafenib versus
trifluridine/tipiracil in patients with metastatic colorectal
cancer refractory to standard chemotherapy (REGOTAS): A Japanese
society for cancer of the colon and rectum multicenter
observational study. Oncologist. 23:7–15. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yoon SE, Lee SJ, Lee J, Park SH, Park JO,
Lim HY, Kang WK, Park YS and Kim ST: The impact of primary tumor
sidedness on the effect of regorafenib in refractory metastatic
colorectal cancer. J Cancer. 10:1611–1615. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Schrock AB, Ouyang C, Sandhu J, Sokol E,
Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, et al: Tumor
mutational burden is predictive of response to immune checkpoint
inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol.
30:1096–1103. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mandal R, Samstein RM, Lee KW, Havel JJ,
Wang H, Krishna C, Sabio EY, Makarov V, Kuo F, Blecua P, et al:
Genetic diversity of tumors with mismatch repair deficiency
influences anti-PD-1 immunotherapy response. Science. 364:485–491.
2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Innocenti F, Ou FS, Qu X, Zemla TJ,
Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM,
Blanke CD, et al: Mutational analysis of patients with colorectal
cancer in CALGB/SWOG 80405 identifies new roles of microsatellite
instability and tumor mutational burden for patient outcome. J Clin
Oncol. 37:1217–1227. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
André T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab in microsatellite-instability-high advanced
colorectal cancer. N Engl J Med. 383:2207–2218. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Grothey A, Prager G and Yoshino T: The
mechanism of action of regorafenib in colorectal cancer: A guide
for the community physician. Clin Adv Hematol Oncol. 12 (Suppl
17):S1–S19. 2019.PubMed/NCBI
|
|
15
|
Arai H, Battaglin F, Wang J, Lo JH, Soni
S, Zhang W and Lenz HJ: Molecular insight of regorafenib treatment
for colorectal cancer. Cancer Treat Rev. 81(101912)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Abou-Elkacem L, Arns S, Brix G, Gremse F,
Zopf D, Kiessling F and Lederle W: Regorafenib inhibits growth,
angiogenesis, and metastasis in a highly aggressive, orthotopic
colon cancer model. Mol Cancer Ther. 12:1322–1331. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cannarile MA, Weisser M, Jacob W, Jegg AM,
Ries CH and Rüttinger D: Colony-stimulating factor 1 receptor
(CSF1R) inhibitors in cancer therapy. J Immunother Cancer.
5(53)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wu RY, Kong PF, Xia LP, Huang Y, Li ZL,
Tang YY, Chen YH, Li X, Senthilkumar R, Zhang HL, et al:
Regorafenib promotes antitumor immunity via inhibiting PD-L1 and
IDO1 expression in melanoma. Clin Cancer Res. 25:4530–4541.
2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Fukuoka S, Hara H, Takahashi N, Kojima T,
Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, et
al: Regorafenib plus nivolumab in patients with advanced gastric or
colorectal cancer: An open-label, dose-escalation, and
dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol.
38:2053–2061. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Karkeni E, Morin SO, Tayeh BB, Goubard A,
Josselin E, Castellano R, Fauriat C, Guittard G, Olive D and Nunès
JA: Vitamin D controls tumor growth and CD8+ T cell
infiltration in breast cancer. Front Immunol.
10(1307)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ducreux M, Petersen LN, Öhler L, Bergamo
F, Metges JP, de Groot JW, Wang JY, Paredes BC, Dochy E,
Fiala-Buskies S, et al: Safety and effectiveness of regorafenib in
patients with metastatic colorectal cancer in routine clinical
practice in the prospective, observational CORRELATE study. Eur J
Cancer. 123:146–154. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Adenis A, de la Fouchardiere C, Paule B,
Burtin P, Tougeron D, Wallet J, Dourthe LM, Etienne PL, Mineur L,
Clisant S, et al: Survival, safety, and prognostic factors for
outcome with regorafenib in patients with metastatic colorectal
cancer refractory to standard therapies: Results from a multicenter
study (REBECCA) nested within a compassionate use program. BMC
Cancer. 16(412)2016.PubMed/NCBI View Article : Google Scholar
|
